Pyrotinib

• CAT Number: I008931
• CAS Number: 1269662-73-8
• Molecular Formula: C32H31ClN6O3
• Molecular Weight: 583.09
• Purity: ≥95%
• Synonyms: Pyrotinib; SHR-1258; SHR1258; SHR 1258; Pyrotinib maleate;(R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• Related CAS: 1397922-61-0
• IUPAC Name: (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
• InChI: InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1
• InChIKey: SADXACCFNXBCFY-IYNHSRRRSA-N
• SMILES: O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5

Pyrotinib (CAT: I008931), also known as SHR-1258, is a dual kinase inhibitor targeting both the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2). It is administered orally and exhibits potential antineoplastic activity. Pyrotinib works by binding to and inhibiting the activity of EGFR and HER2, leading to the inhibition of tumor growth, angiogenesis, and regression in tumor cells expressing these receptors. EGFR and HER2 are receptor tyrosine kinases that are overexpressed in various tumor types, playing critical roles in tumor cell proliferation and the development of tumor blood vessels. Pyrotinib’s dual inhibition of EGFR and HER2 makes it a promising candidate for targeted cancer therapy.